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Objective. To evaluate the efficacy and safety of oral Huangqi formulae for the treatment of stable COPD. Methods. The major
databases were searched until September 2010 and supplemented with a manual search. Randomized controlled trials (RCTs) of
oral Huangqi formulae that reported on lung function, St. George’s Respiratory Questionnaire, symptom improvement and/or
frequency of exacerbations were extracted by two reviewers. The Cochrane tool was used for the assessment of risk of bias in the
included trials. Data were analyzed with RevMan 5.1.2 software. Results. 25 RCTs (1,661 participants) were included. Compared
with conventional therapy (CT) alone, oral Huangqi formulae plus CT increased FEV
1
, and a similar result was found comparing
Huangqi formulae with no treatment. Improvements in SGRQ total score, COPD-related symptoms and reduction of frequency
of exacerbations were found in patients receiving Huangqi formulae plus CT compared to those receiving CT alone or CT plus
placebo. No serious adverse events were reported. However, there were some methodological inadequacies in the included studies.
Conclusions.The benefits ofHuangqi formulae for stable COPDwere promising, but its efficacy and safety have not been established
due to methodological weakness and possible bias in the reported results. Further rigorously designed studies are warranted.
1. Introduction
Chronic obstructive pulmonary disease (COPD) is charac-
terized by airflow limitation and manifests as progressive
dyspnea accompanied by deterioration of lung function [1].
It is a major cause of morbidity, disability, and mortality. The
World Health Organization (WHO) estimated that COPD
ranked fifth in terms of burden of disease worldwide [2]. In
China, COPD affects 8.2% of people aged 40 years or older
[3]. It was the fourth leading cause of death in cities and the
third in rural areas [4].
Studies have shown that pharmacotherapy cannotmodify
the trend of decline in lung function [5, 6]. Chinese herbal
medicine is commonly used for COPD, especially for the
stable stage, in China and other Asian countries. Clinical
studies suggest that herbal formulae that include Huangqi
(Radix Astragalus membranaceus) were effective for stable
COPD [7–31]. It often serves as a principal medicine (i.e.,
the ingredient provides the principal curative action on the
main syndrome or primary symptom [32]) in formulae for
COPD. However, the quality of these studies had not been
evaluated systematically, and some of the reports for the
effects ofHuangqiwere conflicting.Therefore, this systematic
reviewwas conducted to evaluate the evidence for the efficacy
and safety of oral Huangqi for treating stable COPD.
2. Methods
2.1. Search Strategy. Comprehensive searches were per-
formed for three English language databases and five Chinese
databases, which included PubMed (from 1966), Embase
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(from 1985), Cochrane Central Register of Controlled Trials,
Chinese Biomedical Database (CBM, from 1979), China
National Knowledge Infrastructure (CNKI, from 1994), VIP
medicine information system (VMIS, from 1989), Wanfang
(from 1998), and TCM-Online (from 1949), from the incep-
tions of the databases to September 2010, without language
restriction. A manual search was conducted of evidence-
based medicine (EBM) reports on Chinese prescriptions
by Japan Society for Oriental Medicine, EBM special com-
mittee [31]. The focus of the search was randomized con-
trolled trials (RCTs) of oral Huangqi formula for stable
COPD.
Search terms included chronic obstructive pulmonary
disease, chronic bronchitis, emphysema, COPD, chronic
obstructive lung disease, chronic obstructive airway disease,
chronic airflow obstruction, traditional Chinese medicine,
Chinese herbal drugs, complementary and alternative
medicine, phytotherapy, herbs, herbal Medicine, Astragalus,
Huangqi, Beiqi, Milkvetch Root, controlled clinical trial, and
their synonyms. The literature was screened based on title,
abstract, and full text as needed. Full details on the search
strategy are described in the appendix.
2.2. Study Selection. The inclusion criteria were as follows:
(1) RCTs with patients diagnosed with COPD in the stable
stage [1, 33], which manifests as dyspnea, cough, and phlegm
which remain stable or are rather mild; (2) Huangqi formula
(taken orally as decoction, pill, powder, or capsule) alone
or in combination with conventional therapy compared
with placebo, no treatment, or conventional therapy as
controls. Huangqi serves as a principal medicine, defined
as follows: the properties of Huangqi are consistent with
the main aims of the formula, or the dosage of Huangqi
is relatively large (more than 15 g). Conventional therapy
includes bronchodilators (beta2-agonists, anticholinergics,
methylxanthine), corticosteroids, exercise training, smoking
cessation, etc [1]. (3) Outcome measurements include spiro-
metric parameters (forced expiratory volume in one second,
FEV
1
), St. George’s Respiratory Questionnaire (SGRQ) total
score, symptom improvement, and/or frequency of exacer-
bations. The exclusion criteria were (1) trials that included
patients with asthma or other non-COPD disorders; (2) test
interventions that were combined with other TCM thera-
pies such as acupuncture, acupoint injection; (3) Chinese
herbs or other TCM therapies were used in the control
group.
2.3.Data Extraction andRisk of BiasAssessment. Twoauthors
(Lei Wu and Yuanbin Chen) independently assessed studies
based on the inclusion and exclusion criteria. If needed,
two other reviewers (Lin Lin and Zehuai Wen) were con-
sulted. Data on the details of study design, participants,
interventions, controlmedicine, outcomemeasures, numbers
of dropouts, and number and nature of any adverse events
reported were extracted to a predefined form.
Assessment of symptom improvement was based on the
chronic bronchitis section on the Guidance for Clinical
Research on New Drugs of TCM [34], where responses were
categorized into four levels (symptom control, very good,
good, and no effect). The proportion of patient responses for
the following symptoms (cough, sputum, dyspnea, and rale)
was assessed according to the previous levels.
Two authors (Lei Wu and Yuanbin Chen) independently
assessed the risk of bias of the included studies using the
Cochrane tool [35]. Any discrepancies in assessment were
decided by discussion. Other authors (Zehuai Wen and
XinfengGuo) were consulted tomake the final decisionwhen
needed. To verify unclear information on methodology and
therapy, attempts were made to contact the authors of the
original papers via phone, email, or mail. If the authors were
not contactable after 3 times by phone or email, theywere sent
mail and given one month to reply.
2.4. Data Analysis. Data were analyzed by RevMan 5.1.2
(CochraneCollaboration), and Stata 12.0 software (StataCorp
LP, College Station, TX, USA). Dichotomous data were
presented as risk ratio (RR) and continuous outcomes as
mean difference (MD), with 95% confidence intervals (95%
CI). Statistical heterogeneity was assessed by Cochrane’s Q
test. If the analysis showed low heterogeneity (𝑃 ≥ 0.10
and 𝐼2 ≤ 50%), data were synthesized using a fixed-effects
model. Otherwise, a random-effects model was applied.
Subgroup analyses were performed if sufficient numbers of
RCTs were available and sensitivity analyses were undertaken
as required. Publication bias was assessed by funnel plot
analysis if the group included more than five trials [36].
Egger’s test was conducted if it was difficult to determine
whether the funnel plots were symmetrical.
3. Results
3.1. Description of Studies. Of 13,254 potentially relevant
citations, 8,952 were excluded as duplications, 4,012 were
excluded for not meeting the inclusion criteria after reading
the titles and abstracts, and further 265 studies were excluded
after reading the full articles and/or contacting the authors.
Finally, 25 studies (including 1,661 participants) that met all
the selection criteria were included (Figure 1).
Of these 25 studies, 24 were conducted in China [7–
30] and 1 in Japan [31]. Twenty-two were published and 3
were dissertations [20, 22, 26]. All patients were diagnosed as
stable COPD according to the Global Initiative for Chronic
Obstructive Lung Disease (GOLD) or guidelines issued by
Committee of RespiratoryDisease, ChineseMedical Associa-
tion. Disease severity in the included trials ranged frommild
to very severe COPD.The duration of patients’ COPD ranged
from 4 to 30 years.
Nineteen studies compared Huangqi formulae plus con-
ventional therapy with conventional therapy [7, 9–11, 14–
19, 22, 24–31]. Two studies compared Huangqi formulae plus
conventional therapy with placebo plus conventional therapy
[12, 21]. Three studies compared Huangqi formulae with no
treatment [8, 13, 23]. One study compared aHuangqi formula
with conventional therapy [20]. The duration of treatment
varied from 2 weeks to 6 months. One trial reported a 1-year
follow-up period [16].
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Total: 13253 records identified
4302 records after duplicates removed
25 studies included in qualitative synthesis 
24 studies included in quantitative  
synthesis (meta-analysis)
In
clu
de
d
290 full-text articles assessed for eligibility  
PubMed (𝑛 = 370) Embase (𝑛 = 785)
Cochrane library (𝑛 = 263)
CBM (𝑛 = 1063) CNKI (𝑛 = 2225)
VMIS (𝑛 = 2345) Wanfang (𝑛 = 3317)
TCM on line (𝑛 = 2885)
Articles excluded for not meeting inclusion criteria
(𝑛 = 4012)
Articles excluded with reasons (𝑛 = 265):
(1) Not RCT or incorrect randomization method (𝑛 = 83)
(2) Not on stable COPD (𝑛 = 25)
(4) Chinese herbal formulae without Huangqi (𝑛 = 53)
(5) The treatment group received Huangqi formulae
(7) Did not report any of the 4 outcome measures (𝑛 = 22)
Other source:
EBM reports on Chinese prescriptions by
Japan Society for Oriental Medicine,
EBM special committee (𝑛 = 1)
(3) Complicated with asthma or other severe diseases (𝑛 = 9)
combined with other Chinese medicine therapy (𝑛 = 5)
(6) The control group received Chinese herbs (𝑛 = 66)
(8) Huangqi was not used as principal medicine (𝑛 = 2)
Figure 1: Flow diagram showing the trial selection process for the systematic review.
Five studies indicated that Huangqi was used as the
principalmedicine [12, 17, 18, 20, 26]. In the twenty remaining
studies, we consideredHuangqi to be the principal medicinal
when its properties were consistent with the main aims of
the formulae or its dosage was more than 15 g, even when
the authors did not indicate that it was used as a principal
medicinal. The characteristics of the included studies are
summarized in Tables 1 and 2.
3.2. Risk of Bias of the Included Studies. After attempts at
verification by contacting the authors of the original papers
through phone, e-mail, or mail, 14 of the included trials still
lacked a detailed description of the method of randomiza-
tion, and 19 trials did not indicate whether blinding was
applied. Only two trials described the method of generation
of randomization sequence, allocation concealment, double
blinding, and placebo manufacturing method. Two trials
reported dropouts; one of them explained the reason was
loss of contact with the participants, and the other did not
provide reasons. No trials reported whether they had used
intention-to-treat analysis. Selective outcome reporting was
judged as low risk of bias in 2 trials, uncertain risk in 19
trials, and high risk in 4 trials. No study had a registered or
published protocol; so, judgment was based on the outcome
measures specified in the method section of the study and
was informed by discussion with the author when possible.
Most of the included trials lacked a sample size calculation
(Figure 2).
3.3. Publication Bias. Thenumber of studies reporting SGRQ
scores and the frequency of exacerbations was less than five;
so, a funnel plot was not applicable. The characteristics of
studies reporting FEV
1
were different, and the number of
trials in each subgroup was less than five; so, funnel plots
were also not applicable. For symptom improvement, the
symmetry of the funnel plot was not clear; so, Egger’s test was
conducted. It indicated that the effect of publication bias was
not significant (𝑡 = 1.39, 95% CI, −0.69 to 2.48, 𝑃 = 0.215)
(Figure 3).
4 Evidence-Based Complementary and Alternative Medicine
Table 1: Characteristics of included studies.
First author,
year [Ref] Location
No. of
participants
(R/A)
Age
Mean ± SD
(years)
Severity of COPD
COPD History
Mean ± SD
(years)
Xu
2007 [7] China
T: 30/30
C: 30/30
T: 67 ± 19.31
C: 64 ± 20.97
T: II: 12, III: 18
C: II: 13, III: 17 NR
Hong
2004 [8] China
T: 20/20
C: 18/18
T: 67.70 ± 5.68
C: 66.89 ± 5.57
T: II: 5, III: 15
C: II: 4, III: 14
T: 15.05 ± 5.54
C: 14.33 ± 7.28
Jia
2007 [9] China
T: 30/30
C: 25/25
T: 61.6 ± 6.1
C: 63.2 ± 5.3
T: I: 5, II: 18, III: 7
C: I: 3, II: 17, III: 5
T: 15.25 ± 4.01
C: 13.12 ± 3.38
Wang
2005 [10] China
T: 20/20
C: 20/20
T: 59.4 ± 7.5
C: 60.9 ± 7.9
T: II A: 8, II B: 9, III: 3
C: II A: 9, II B: 9, III: 2
T: 11.2 ± 4.1
C: 11.8 ± 4.5
Cui
2004 [11] China
T: 20/20
C: 20/20
T: 62.5
C: 61.5 NR NR
Lin
2003 [12] China
T: 30/30
C: 30/30
T: 62
C: 60.5 NR
T: 16 ± NR
C: 15.4 ± NR
Zhang
2006 [13] China
T: 24/24
C: 22/22
T: 66.70 ± 6.60
C: 67.89 ± 4.57
T: II: 5, III: 19
C: II: 4, III: 18
T: 14.05 ± 6.54
C: 15.33 ± 5.0
Feng
2006 [14] China
T: 36/36
C: 33/33 48–73 NR NR
Zhao
2003 [15] China
T: 15/15
C: 15/15
T: 51.71 ± 8.10
C: 48.87 ± 7.73 NR NR
Li
2006 [16] China
T: 85/85
C: 40/40
T: 53
C: 49 NR
T: 22 ± NR
C: 25 ± NR
Xu
2004 [17] China
T: 25/25
C: 24/24
T: 63 ± 6.4
C: 62.9 ± 7.0 NR
T: 17.7 ± 9.5
C: 16.9 ± 12.3
Luo
2002 [18] China
T: 36/36
C: 20/20
T: 63.86 ± 12.56
C: 63.90 ± 12.56 NR
T: 20.36 ± 11.21
C: 19.70 ± 10.00
Wang
2007 [19] China
T: 30/30
C: 30/30
T: 62.8
C: 60.5 NR
T: 15 ± NR
C: 18 ± NR
Huang
2008 [20] China
T: 16/16
C: 16/16
T: 74.75 ± 6.17
C: 73.81 ± 3.71
T: II: 8, III: 8
C: II: 8, III: 8 NR
He
2010 [21] China
T: 49/49
C: 49/49 75 ± 5.8 NR 11.25 ± 5.86
Guan
2006 [22] China
T: 37/30
C: 37/30
T: 65.5 ± 8.21
C: 65.10 ± 12.42
T: 0:7, I: 4, II: 4, III: 15
C: 0:4, I: 5, II: 11, III: 10 NR
Wei
2007 [23] China
T: 60/60
C: 60/60 Not reported NR NR
Ma
2010 [24] China
T: 30/30
C: 30/30 Not reported I to II NR
Ding
2009 [25] China
T: 53/53
C: 53/53
T: 61.23 ± 3.65
C: 62.16 ± 3.03
T: I: 35, II: 18
C: I: 31, II: 22
T: 17.21 ± 3.02
C: 16.79 ± 2.41
Zhou
2005 [26] China
T: 30/30
C: 30/30
T: 63.63 ± 7.77
C: 64.83 ± 7.37 NR NR
Hu, 2009
[27] China
T: 35/35
C: 32/32
T: 64.7 ± 7.5
C: 63.2 ± 5.4 NR NR
Chen
2009 [28] China
T: 30/30
C: 30/30 70.1 NR NR
Liang
2009 [29] China
T: 32/32
C: 33/33
T: 69.73
C: 70.69
T: I: 0, II: 13, III: 12, IV: 7
C: I: 0, II: 15, III: 12, IV: 6
T: 17.32 ±NR
C: 17.02 ± NR
Zhang
2009 [30] China
T: 60/56
C: 60/48 68.4 NR NR
Tatsumi
2002 [31] Japan
T: 34/34
C: 37/37 Not reported II to III NR
T: treatment; C: control; NR: not reported; R: number of subjects randomized; A: number of subjects analysed; SD: standard deviation.
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Figure 2: Summary of assessment of risk of bias for each included
study.
3.4. Outcome Measures
3.4.1. Spirometric Parameters. Subgroup analyses were per-
formed according the type of comparison (Figure 4). Sub-
group 1 compared Huangqi formulae plus conventional ther-
apy with conventional therapy alone [11, 16–19, 25, 27, 28, 30].
FEV
1
increased 0.27 L (95% CI: 0.11 to 0.43) based on 9
0.2
0.15
0.1
0.05
0
SE
 (l
og
[R
R]
)
0.5 0.7 1 1.5 2
RR
Figure 3: Funnel plot of publication bias using symptom improve-
ment.
trials, but there was high heterogeneity in this subgroup.
So, further analyses were performed according to duration
of treatment as follows: more than, equal to, or less than
3 months. The former 2 categories had low heterogeneity.
There was a significant difference in FEV
1
in the trials which
had durations of more than 3 months (MD 0.33, 95% CI:
0.20 to 0.46) [17, 19, 30] and no significant difference in
those of 3 months duration (MD 0.07, 95% CI: −0.07 to 0.20)
[18, 28]. For trials of less than 3 months [11, 16, 25, 27],
FEV
1
increased (MD 0.36, 95% CI: 0.29 to 0.43), but there
was heterogeneity. So, sensitivity analysis was conducted. It
produced lowheterogeneitywith a significant difference (MD
0.49, 95% CI: 0.41 to 0.57) when one trial [16] was removed
because the age distribution of participants differed from the
other trials.
Subgroup 2 compared Huangqi formulae with no treat-
ment [8, 23]. FEV
1
increased significantly by 0.19 L based on
2 trails (95% CI: 0.10 to 0.28).
3.4.2. Quality of Life. Patients receiving Huangqi formulae
plus conventional therapy showed a significantly greater
reduction in SGRQ total score (MD −5.04, 95% CI: −7.48 to
−2.61) than those receiving conventional therapy alone, based
on 3 trials [24, 28, 30] (Figure 5).
3.4.3. Symptom Improvement. Patients receiving Huangqi
formulae plus conventional therapy were more likely to show
improvements in COPD-related symptoms (RR: 1.21, 95%CI:
1.12 to 1.31) when comparedwith those receiving conventional
therapy alone or conventional therapy plus placebo, based on
8 trials [12, 14, 16, 20, 25–27, 29] (Figure 6).
3.4.4. Frequency of Exacerbations. Four trials reported fre-
quency of exacerbations at pre- and posttreatment [16, 17,
21, 24]. Compared with placebo plus conventional therapy or
conventional therapy alone, the frequency of exacerbations
in patients receiving Huangqi formulae plus conventional
therapy was significantly reduced (MD −0.97, 95% CI: −1.57
to −0.37), but the heterogeneity was high (Figure 7). This
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Experimental Control Mean difference Mean difference
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Heterogeneity: 𝜒2 = 1.45, 𝑑𝑓 = 2 (𝑃 = 0.49); 𝐼2 = 0%
Test for overall effect: 𝑍 = 11.84 (𝑃 < 0.00001)
Heterogeneity: 𝜒2 = 0.66, 𝑑𝑓 = 1 (𝑃 = 0.42); 𝐼2 = 0%
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0.2 [−0.14, 0.54]
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∗CT: conventional therapy
−0.04
−1 −0.5 0 0.5 1
Favours control Favours experimental
5.1.1 Huangqi formulae plus CT∗versus CT, treatment duration < 3months
5.1.2 Huangqi formulae plus CT versus CT, treatment duration = 3months
5.1.3 Huangqi formulae plus CT versus CT, treatment duration > 3months
5.1.4 Huangqi formulae versus no treatment
Figure 4: Forest plot ofHuangqi formulae plus conventional therapy versus conventional therapy, or Huangqi formulae versus no treatment
in patients with stable COPD: change in FEV
1
(L).
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Figure 5: Comparison of Huangqi formulae plus conventional therapy versus conventional therapy alone in patients with stable COPD:
change in SGRQ total scores.
appeared due to variation between trials in terms of the con-
trol interventions used, duration, and trial quality. Overall,
the better result appeared to be of He et al., 2010 [21].
3.5. Adverse Events. Six trials reported that no adverse events
occurred [7, 8, 11, 21, 26, 31]. One trial (60 participants)
reported hoarseness in the control group treated by salme-
terol/fluticasone [28], but there was no causality assessment
for this adverse event. The other trials did not report adverse
events; so, there was insufficient data to assess whether the
combination of Huangqi formulae plus conventional therapy
affected the adverse event rate.
4. Discussion
This systematic review includes 24 RCTs conducted in China
and 1 RCT in Japan. All RCTs employed the herb Huangqi as
a principal herb in the herbal formulae used in the test arms,
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Figure 6: Comparison of Huangqi formulae plus conventional therapy versus conventional therapy alone in patients with stable COPD:
overall symptom improvement (defined as “good” or above).
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Figure 7: Comparison of Huangqi formulae plus conventional therapy versus placebo plus conventional therapy or conventional alone in
patients with stable COPD: change in frequency of exacerbations.
and all studies only included patients assessed as suffering
stable COPD. The comparators were mostly conventional
therapy, but this was variable and was not clearly specified
in some studies. This is likely to have been a source of
heterogeneity in the meta-analyses, but it also reflects usual
care since patients with stable COPD would typically receive
a variety of conventional therapies which may be varied
according to response and individual need. Eight studies were
of six months, while the others were of shorter treatment
duration and only one had a followup at one year; so, the
results can only be considered relevant to the relatively short-
term management of COPD.
Themeta-analysis results indicate that the use ofHuangqi
formulae could significantly improve lung function mea-
sured as FEV
1
when compared with no treatment based
on two studies, and it produced an additional improvement
when combined with conventional therapies based on 9
studies, four of which were of over three months duration.
The incidence of exacerbations also appeared to decline
when Huangqi formulae were combined with conventional
therapies. Improvements in quality of life based on SGRQ
were evident, but this was based on only three studies.
Also, theseHuangqi-containing formulae appeared to be well
tolerated, even when combined with conventional medica-
tions, since seven studies reported that no adverse eventswere
noted.
All the included trials demonstrated at least some
methodological deficiencies leading to potential risks of bias.
Only eleven provided evidence of adequate randomization
procedures, and only three were effectively blinded to par-
ticipants and investigators. Consequently, the results should
be interpreted with caution. Therefore, the potential benefits
of oralHuangqi formulae for stable COPD need to be further
appraised through trials that employ rigorous methodology
and include adequate assessment of the safety profiles of the
interventions. In addition, we found that the reporting of
trial methods and procedures was frequently unclear and
insufficient. Therefore, we suggest that all reports of RCTs
published in China should be required to comply with the
CONSORT statement [37] and the publication of protocols
should be encouraged.
There has been increasing interest in complementary and
alternative medicine (CAM) for the treatment of COPD,
especially the use of Chinese herbal medicines [38, 39]. A
recent cross-sectional study inAustralia suggested that nearly
one in five (17.3%) individuals withmoderate to severe COPD
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had used some form of herbal preparation [39]. Therefore,
reviews of the state of the evidence base are essential.
From viewpoint of TCM, patients with stable COPD
usually manifest with Qi-deficiency syndrome [40]. One
of the characteristics of Qi-deficiency is that the patient
easily suffers from colds which commonly lead to acute
exacerbations of COPD.Huangqi is one of the principal herbs
used for reinforcingQi. It has beenwidely used for preventing
and alleviating common colds; so, its clinical use in COPD
is predicated on a putative benefit in preventing colds and
reducing COPD exacerbations.
From the experimental perspective, one line of research
into Huangqi has focused on its effects on inflammation.
The main pathological characteristic of COPD is chronic
airway inflammation involving a number of proinflammatory
mediators and cytokines. Also, oxidative stress is increased
in COPD, which amplifies inflammation and may result
in corticosteroid resistance. An invivo study suggests that
Huangqi may reduce inflammatory infiltration and inhibit
the inflammatory response in the airway through downreg-
ulating the expression of TNF-𝛼 and IL-8 [41]. Flavonoids in
Huangqimay protect the erythrocyte membrane from attack
by free radicals and appear to eliminate free radicals [42].
One study has shown that airway inflammation induced by
cigarette smoke was reversed by astragaloside IV (AST IV),
another active constituent of Huangqi, in a dose-dependent
fashion. This effect appeared due to its anti-inflammatory
and antioxidant properties, including NF-𝜅B inactivation
[43]. Other studies suggested that AST IV possesses anti-
inflammatory and immune regulation activity and can be
used for preventing asthma attacks [44]. The previous phar-
macological properties of Huangqi may at least partially
explain the clinical benefits reported by the studies included
in this paper.
An earlier paper [45] evaluated the effects of a diverse
range of herbal medicines in COPD, and a subsequent
paper narrowed the focus to ginseng and ginseng-containing
formulae [46]. The strengths of this paper are it focuses only
on formulae that share the same principal ingredient and
there is experimental evidence that supports the application
of this herb as a modulator of inflammation.
The main limitations to this paper are the potential
sources of bias due to methodological defects and inadequa-
cies in reporting. Although publication bias was not a major
issue, the previous issues potentially lead to overreporting of
positive results, selective reporting of outcomemeasures, and
underreporting of adverse events. Also, the use of a diversity
of conventional therapies as comparators makes it difficult
to assess the magnitude of any effects and to interpret their
clinical significance.
Therefore, the potential benefits of oralHuangqi formulae
for stable COPD evident in this paper need to be further
appraised through suitably powered clinical trials that employ
standardized conventional therapies as comparators over
a sufficient period to determine whether any effects are
of sufficient clinical relevance to warrant modification to
current best practice for the management of stable COPD.
5. Conclusions
OralHuangqi formulae appear beneficial in terms of improv-
ing lung function, quality of life, and symptoms and in
reducing the incidence of exacerbations for patients with
stable COPD, but these apparent benefits require further
appraisal through higher quality trials that strictly adhere to
methodological principles and procedures.
Appendix
Search Strategies
English Databases
#1: Chronic obstructive pulmonary disease OR COPD
OR emphysema OR Chronic obstructive lung disease
OR Chronic obstructive airway disease OR emphy-
sema, pulmonary disease OR Airflow obstruction,
Chronic OR Chronic Airflow Obstruction OR Pul-
monary Emphysema
#2: Traditional Chinese Medicine OR Chinese Tradi-
tional Medicine OR Chinese Herbal Drugs OR Chi-
nese Drugs, Plant OR Medicine, Traditional OR Eth-
nomedicine OR Ethnobotany OR Medicine, Kampo
OR TCMOR Alternative Medicine OR Complemen-
tary Medicine OR Phytotherapy OR Herbology OR
Plants, Medicinal OR Plant Preparations OR Plant
Extracts OR Plants, Medicine ORMateriaMedica OR
Single Prescription OR Herbs OR Chinese Medicine
Herb OR Herbal Medicine
#3: Clinical Trial OR clinical study OR biomedical
research OR Controlled Trial OR Controlled study
OR random control Trial OR random control study
OR Multicenter Study OR random allocation OR
double-blind OR single-blind OR comparative study
OR evaluation studyOR follow-up studyORprospec-
tive study OR research design OR control group OR
placebo control OR dummy control OR blinding OR
clinical research OR medical trial OR in vivo study
OR case control study OR intervention study
#4: Astragalus OR Milkvetch OR Huangqi OR Beiqi OR
Milkvetch Root
#5: #1 AND #2 AND #3
#6: #1 AND #3 AND #4
#7: #5 OR #6.
Chinese Databases (search by using simplified Chinese
character)
#1: Man Xing Zu Sai Xing Fei Bing (Chronic obstructive
pulmonary disease) OR Man Xing Zu Sai Xing Fei
Ji Bing (Chronic obstructive pulmonary disease) OR
Man Zu Fei (Chronic obstructive pulmonary disease)
OR Man Xing Zu Sai Xing Fei Bu Ji Bing (Chronic
obstructive lung disease) OR COPD OR Zu Sai Xing
Fei Ji Bing (Obstructive pulmonary disease) OR Zu
Sai Xing Fei Bing (Obstructive pulmonary disease)
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OR Man Xing Zu Sai Xing Fei Qi Zhong (Chronic
obstructive pulmonary emphysema) OR Zu Sai Xing
Fei Qi Zhong (Obstructive pulmonary emphysema)
#2: Zhong Yi (Traditional Chinese Medicine) OR Guo Yi
(Chinese Medicine) OR Chuan Tong Yi Xue (Tradi-
tional Medicine) OR Han Fang (Kampo) OR Han Yi
(Kampo Medicine) OR Dong Yi (Vietnamese tradi-
tional medicine) ORMin Zu Yi Yao (Ethnomedicine)
OR Bian Zheng (Syndrome Differentiation) OR Zhi
Fa (Therapeutic Method) OR Zhi Ze (Therapeutic
Principle) OR Zhong Xi Yi (Chinese and Western
medicine) OR Zhong Xi Yi Jie He (Integration of
Chinese and Western medicine) OR Zhong Xi Yao
(Chinese and Western medicine) OR Zhong Yao
(Chinese Medicine) OR Cao Yao (Herbal Medicine)
OR Zhong Cheng Yao (Chinese patent medicine) OR
Zhi Wu Yao (Phytomedicine) OR Zhen Ci (acupunc-
ture) OR Jiu (moxibustion) OR Jing Luo (merid-
ian/channel) OR Xue Wei (acupoint) OR Shui Zhen
(Aqueous acupuncture) OR Er Xue (ear point) OR Er
Zhen (ear acupuncture) OR Fang Xue (Bloodletting)
OR Ci Xue (pricking blood) OR Ci Luo (collateral
pricking)ORDianZhen (electronic acupuncture)OR
Ba Guan (cupping) OR Tui Na (tuina) OR An Mo
(massage) ORMei Hua Zhen (plum-blossom needle)
OR San Leng Zhen (three-edged needling) OR Mai
Xian (catgut-embedding) ORYao Yun (hotmedicinal
compress) OR Guan Chang (enema)
#3: Huang Qi (Milkvetch) OR Bei Qi (Milkvetch) OR
Huang Qi (variant of Chinese character, Milkvetch)
#4: #1 AND #2
#5: #1 AND #3
#6: #4 OR #5.
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